Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2016, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 2, 23, 129, 99, 5, 107, 15 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 15, 9 and 5 molecules, respectively.Non-Hodgkin Lymphoma.
Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
3SBio Inc
4SC AG
AB Science SA
AbbVie Inc
Acetylon Pharmaceuticals Inc
Actelion Ltd
Actinium Pharmaceuticals Inc
ADC Therapeutics Sarl
Affimed GmbH
Allinky Biopharma
Altor BioScience Corp
Amgen Inc
Angimmune LLC
arGEN-X BV
Arno Therapeutics Inc
Arrien Pharmaceuticals LLC
Arvinas Inc
Asana BioSciences LLC
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Aurigene Discovery Technologies Ltd
Bayer AG
BeiGene Ltd
Bellicum Pharmaceuticals Inc
Bio-Path Holdings Inc
BioAtla LLC
Biocon Ltd
Biogen Inc
Biogenomics Ltd
BioInvent International AB
BioLineRx Ltd
Bionovis SA
BioNTech AG
BioSight Ltd
Biothera Pharmaceutical Inc
bluebird bio Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Calimmune Inc
Calithera Biosciences Inc
Celgene Corp
Cell Medica Ltd
Cell Source Inc
Cell>Point LLC
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellectis SA
Celltrion Inc
Cellular Biomedicine Group Inc
Celon Pharma Sp z oo
CerRx Inc
Chipscreen Biosciences Ltd
Clevexel Pharma SA
Coherus BioSciences Inc
Constellation Pharmaceuticals Inc
Cornerstone Pharmaceuticals Inc
CrystalGenomics Inc
CSPC Pharmaceutical Group Limited
CTI BioPharma Corp
Curis Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Company Ltd
Dynavax Technologies Corp
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Company
EpiZyme Inc
Erytech Pharma SA
Evotec AG
F. Hoffmann-La Roche Ltd
Formula Pharmaceuticals Inc
Galderma SA
Gamida Cell Ltd
Genentech Inc
Genor BioPharma Co Ltd
Genosco
Gilead Sciences Inc
GlaxoSmithKline Plc
Grupo Ferrer Internacional SA
H3 Biomedicine Inc
Humorigin Biotechnology Corp
Hutchison MediPharma Ltd
iDD biotech SAS
IGF Oncology LLC
Ignyta Inc
Immune Design Corp
ImmunoGen Inc
Immunomedics Inc
Immunovaccine Inc
Incyte Corp
Inflection Biosciences Ltd
Innate Pharma SA
Innovent Biologics Inc
Japan Tobacco Inc
JHL Biotech Inc
Johnson & Johnson
Juno Therapeutics Inc
Kainos Medicine Inc
Karyopharm Therapeutics Inc
Kite Pharma Inc
Komipharm International Co Ltd
Kyowa Hakko Kirin Co Ltd
LFB SA
Mabion SA
mAbxience SA
MacroGenics Inc
MedImmune LLC
Medivation Inc
MEI Pharma Inc
Merck & Co Inc
Merck KGaA
Mesoblast Ltd
Millennium Pharmaceuticals Inc
miRagen Therapeutics Inc
Mirati Therapeutics Inc
Molecular Templates Inc
Moleculin Biotech Inc
Molplex Ltd
MorphoSys AG
Mundipharma International Ltd
NantKwest Inc
Neumedicines Inc
Nimbus Therapeutics LLC
Nordic Nanovector ASA
NovaLead Pharma Pvt Ltd
Novartis AG
NovImmune SA
Oncobiologics Inc
Onconova Therapeutics Inc
OncoSec Medical Inc
Oncternal Therapeutics Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Oxford BioTherapeutics Ltd
OXIS International, Inc.
Panacea Biotec Ltd
Patrys Ltd
Pfizer Inc
Pharma Mar SA
Pharmacyclics Inc
Philogen SpA
Polaris Pharmaceuticals Inc
Portola Pharmaceuticals Inc
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
Respiratorius AB
Rhizen Pharmaceuticals SA
Richter Gedeon Nyrt
Sandoz International GmbH
Sanofi
Sareum Holdings Plc
SciTech Development LLC
Seattle Genetics Inc
Selvita SA
Senhwa Biosciences Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Henlius Biotech Co Ltd
Shanghai Pharmaceutical Co Ltd
SialoTec GmbH
Sigma-Tau SpA
Simcere Pharmaceutical Group
Solasia Pharma KK
Soligenix Inc
Sorrento Therapeutics Inc
Spectrum Pharmaceuticals Inc
Stemline Therapeutics Inc
Supratek Pharma Inc
Sutro Biopharma Inc
Taiho Pharmaceutical Co Ltd
Taiwan Liposome Company Ltd
Takara Bio Inc
Takeda Pharmaceutical Company Ltd
Targazyme Inc
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries Ltd
TG Therapeutics Inc
The International Biotechnology Center (IBC) Generium
Theravectys SA
TRACON Pharmaceuticals Inc
Transgene Biotek Ltd
Transgene SA
Trillium Therapeutics Inc
United BioPharma Inc
Unum Therapeutics Inc
Verastem Inc
Vivolux AB
Xencor Inc
Xenetic Biosciences (UK) Ltd
ZIOPHARM Oncology Inc
Zymeworks Inc
'
Table of Contents
Table of Contents 2
Introduction 11
Non-Hodgkin Lymphoma Overview 12
Therapeutics Development 13
Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 15
Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 32
Non-Hodgkin Lymphoma - Pipeline Products Glance 34
Non-Hodgkin Lymphoma - Products under Development by Companies 38
Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 88
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 92
Non-Hodgkin Lymphoma - Therapeutics Assessment 287
Drug Profiles 354
Non-Hodgkin Lymphoma - Dormant Projects 1528
Non-Hodgkin Lymphoma - Discontinued Products 1561
Non-Hodgkin Lymphoma - Product Development Milestones 1574
Appendix 1584
List of Tables
Number of Products under Development for Non-Hodgkin Lymphoma, H2 2016 58
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2016 59
Number of Products under Development by Companies, H2 2016 61
Number of Products under Development by Companies, H2 2016 (Contd..1) 62
Number of Products under Development by Companies, H2 2016 (Contd..2) 63
Number of Products under Development by Companies, H2 2016 (Contd..3) 64
Number of Products under Development by Companies, H2 2016 (Contd..4) 65
Number of Products under Development by Companies, H2 2016 (Contd..5) 66
Number of Products under Development by Companies, H2 2016 (Contd..6) 67
Number of Products under Development by Companies, H2 2016 (Contd..7) 68
Number of Products under Development by Companies, H2 2016 (Contd..8) 69
Number of Products under Development by Companies, H2 2016 (Contd..9) 70
Number of Products under Development by Companies, H2 2016 (Contd..10) 71
Number of Products under Development by Companies, H2 2016 (Contd..11) 72
Number of Products under Development by Companies, H2 2016 (Contd..12) 73
Number of Products under Development by Companies, H2 2016 (Contd..13) 74
Number of Products under Development by Companies, H2 2016 (Contd..14) 75
Number of Products under Development by Companies, H2 2016 (Contd..15) 76
Number of Products under Investigation by Universities/Institutes, H2 2016 77
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 78
Comparative Analysis by Late Stage Development, H2 2016 79
Comparative Analysis by Clinical Stage Development, H2 2016 80
Comparative Analysis by Early Stage Development, H2 2016 81
Comparative Analysis by Unknown Stage Development, H2 2016 82
Products under Development by Companies, H2 2016 83
Products under Development by Companies, H2 2016 (Contd..1) 84
Products under Development by Companies, H2 2016 (Contd..2) 85
Products under Development by Companies, H2 2016 (Contd..3) 86
Products under Development by Companies, H2 2016 (Contd..4) 87
Products under Development by Companies, H2 2016 (Contd..5) 88
Products under Development by Companies, H2 2016 (Contd..6) 89
Products under Development by Companies, H2 2016 (Contd..7) 90
Products under Development by Companies, H2 2016 (Contd..8) 91
Products under Development by Companies, H2 2016 (Contd..9) 92
Products under Development by Companies, H2 2016 (Contd..10) 93
Products under Development by Companies, H2 2016 (Contd..11) 94
Products under Development by Companies, H2 2016 (Contd..12) 95
Products under Development by Companies, H2 2016 (Contd..13) 96
Products under Development by Companies, H2 2016 (Contd..14) 97
Products under Development by Companies, H2 2016 (Contd..15) 98
Products under Development by Companies, H2 2016 (Contd..16) 99
Products under Development by Companies, H2 2016 (Contd..17) 100
Products under Development by Companies, H2 2016 (Contd..18) 101
Products under Development by Companies, H2 2016 (Contd..19) 102
Products under Development by Companies, H2 2016 (Contd..20) 103
Products under Development by Companies, H2 2016 (Contd..21) 104
Products under Development by Companies, H2 2016 (Contd..22) 105
Products under Development by Companies, H2 2016 (Contd..23) 106
Products under Development by Companies, H2 2016 (Contd..24) 107
Products under Development by Companies, H2 2016 (Contd..25) 108
Products under Development by Companies, H2 2016 (Contd..26) 109
Products under Development by Companies, H2 2016 (Contd..27) 110
Products under Development by Companies, H2 2016 (Contd..28) 111
Products under Development by Companies, H2 2016 (Contd..29) 112
Products under Development by Companies, H2 2016 (Contd..30) 113
Products under Development by Companies, H2 2016 (Contd..31) 114
Products under Development by Companies, H2 2016 (Contd..32) 115
Products under Development by Companies, H2 2016 (Contd..33) 116
Products under Development by Companies, H2 2016 (Contd..34) 117
Products under Development by Companies, H2 2016 (Contd..35) 118
Products under Development by Companies, H2 2016 (Contd..36) 119
Products under Development by Companies, H2 2016 (Contd..37) 120
Products under Development by Companies, H2 2016 (Contd..38) 121
Products under Development by Companies, H2 2016 (Contd..39) 122
Products under Development by Companies, H2 2016 (Contd..40) 123
Products under Development by Companies, H2 2016 (Contd..41) 124
Products under Development by Companies, H2 2016 (Contd..42) 125
Products under Development by Companies, H2 2016 (Contd..43) 126
Products under Development by Companies, H2 2016 (Contd..44) 127
Products under Development by Companies, H2 2016 (Contd..45) 128
Products under Development by Companies, H2 2016 (Contd..46) 129
Products under Development by Companies, H2 2016 (Contd..47) 130
Products under Development by Companies, H2 2016 (Contd..48) 131
Products under Development by Companies, H2 2016 (Contd..49) 132
Products under Investigation by Universities/Institutes, H2 2016 133
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 134
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 135
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 136
Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H2 2016 137
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2016 138
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H2 2016 139
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H2 2016 140
Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 141
Non-Hodgkin Lymphoma - Pipeline by Actelion Ltd, H2 2016 142
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 143
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H2 2016 144
Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H2 2016 145
Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H2 2016 146
Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corp, H2 2016 147
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H2 2016 148
Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H2 2016 149
Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H2 2016 150
Non-Hodgkin Lymphoma - Pipeline by Arno Therapeutics Inc, H2 2016 151
Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 152
Non-Hodgkin Lymphoma - Pipeline by Arvinas Inc, H2 2016 153
Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences LLC, H2 2016 154
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H2 2016 155
Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H2 2016 156
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H2 2016 157
Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics Inc, H2 2016 158
Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 159
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H2 2016 160
Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, H2 2016 161
Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 162
Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings Inc, H2 2016 163
Non-Hodgkin Lymphoma - Pipeline by BioAtla LLC, H2 2016 164
Non-Hodgkin Lymphoma - Pipeline by Biocon Ltd, H2 2016 165
Non-Hodgkin Lymphoma - Pipeline by Biogen Inc, H2 2016 166
Non-Hodgkin Lymphoma - Pipeline by Biogenomics Ltd, H2 2016 167
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H2 2016 168
Non-Hodgkin Lymphoma - Pipeline by BioLineRx Ltd, H2 2016 169
Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H2 2016 170
Non-Hodgkin Lymphoma - Pipeline by BioNTech AG, H2 2016 171
Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd, H2 2016 172
Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H2 2016 173
Non-Hodgkin Lymphoma - Pipeline by bluebird bio Inc, H2 2016 174
Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 175
Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical Inc, H2 2016 176
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 177
Non-Hodgkin Lymphoma - Pipeline by Calimmune Inc, H2 2016 178
Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences Inc, H2 2016 179
Non-Hodgkin Lymphoma - Pipeline by Celgene Corp, H2 2016 180
Non-Hodgkin Lymphoma - Pipeline by Cell Medica Ltd, H2 2016 182
Non-Hodgkin Lymphoma - Pipeline by Cell Source Inc, H2 2016 183
Non-Hodgkin Lymphoma - Pipeline by Cell>Point LLC, H2 2016 184
Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics Inc, H2 2016 185
Non-Hodgkin Lymphoma - Pipeline by Cellectar Biosciences Inc, H2 2016 186
Non-Hodgkin Lymphoma - Pipeline by Cellectis SA, H2 2016 187
Non-Hodgkin Lymphoma - Pipeline by Celltrion Inc, H2 2016 188
Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H2 2016 189
Non-Hodgkin Lymphoma - Pipeline by Celon Pharma Sp z oo, H2 2016 190
Non-Hodgkin Lymphoma - Pipeline by CerRx Inc, H2 2016 191
Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H2 2016 192
Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SA, H2 2016 193
Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences Inc, H2 2016 194
Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals Inc, H2 2016 195
Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 196
Non-Hodgkin Lymphoma - Pipeline by CrystalGenomics Inc, H2 2016 197
Non-Hodgkin Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 198
Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp, H2 2016 199
Non-Hodgkin Lymphoma - Pipeline by Curis Inc, H2 2016 200
Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 201
Non-Hodgkin Lymphoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 202
Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corp, H2 2016 203
Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics Inc, H2 2016 204
Non-Hodgkin Lymphoma - Pipeline by Eisai Co Ltd, H2 2016 205
Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H2 2016 206
Non-Hodgkin Lymphoma - Pipeline by EpiZyme Inc, H2 2016 207
Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H2 2016 208
Non-Hodgkin Lymphoma - Pipeline by Evotec AG, H2 2016 209
Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 210
Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals Inc, H2 2016 211
Non-Hodgkin Lymphoma - Pipeline by Galderma SA, H2 2016 212
Non-Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd, H2 2016 213
Non-Hodgkin Lymphoma - Pipeline by Genentech Inc, H2 2016 214
Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co Ltd, H2 2016 215
Non-Hodgkin Lymphoma - Pipeline by Genosco, H2 2016 216
Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences Inc, H2 2016 217
Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016 218
Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional SA, H2 2016 219
Non-Hodgkin Lymphoma - Pipeline by H3 Biomedicine Inc, H2 2016 220
Non-Hodgkin Lymphoma - Pipeline by Humorigin Biotechnology Corp, H2 2016 221
Non-Hodgkin Lymphoma - Pipeline by Hutchison MediPharma Ltd, H2 2016 222
Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H2 2016 223
Non-Hodgkin Lymphoma - Pipeline by IGF Oncology LLC, H2 2016 224
Non-Hodgkin Lymphoma - Pipeline by Ignyta Inc, H2 2016 225
Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp, H2 2016 226
Non-Hodgkin Lymphoma - Pipeline by ImmunoGen Inc, H2 2016 227
Non-Hodgkin Lymphoma - Pipeline by Immunomedics Inc, H2 2016 228
Non-Hodgkin Lymphoma - Pipeline by Immunovaccine Inc, H2 2016 229
Non-Hodgkin Lymphoma - Pipeline by Incyte Corp, H2 2016 230
Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Ltd, H2 2016 231
Non-Hodgkin Lymphoma - Pipeline by Innate Pharma SA, H2 2016 232
Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics Inc, H2 2016 233
Non-Hodgkin Lymphoma - Pipeline by Japan Tobacco Inc, H2 2016 234
Non-Hodgkin Lymphoma - Pipeline by JHL Biotech Inc, H2 2016 235
Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H2 2016 236
Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc, H2 2016 237
Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine Inc, H2 2016 238
Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics Inc, H2 2016 239
Non-Hodgkin Lymphoma - Pipeline by Kite Pharma Inc, H2 2016 240
Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co Ltd, H2 2016 241
Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 242
Non-Hodgkin Lymphoma - Pipeline by LFB SA, H2 2016 243
Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H2 2016 244
Non-Hodgkin Lymphoma - Pipeline by mAbxience SA, H2 2016 245
Non-Hodgkin Lymphoma - Pipeline by MacroGenics Inc, H2 2016 246
Non-Hodgkin Lymphoma - Pipeline by MedImmune LLC, H2 2016 247
Non-Hodgkin Lymphoma - Pipeline by Medivation Inc, H2 2016 248
Non-Hodgkin Lymphoma - Pipeline by MEI Pharma Inc, H2 2016 249
Non-Hodgkin Lymphoma - Pipeline by Merck & Co Inc, H2 2016 250
Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H2 2016 251
Non-Hodgkin Lymphoma - Pipeline by Mesoblast Ltd, H2 2016 252
Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 253
Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics Inc, H2 2016 254
Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc, H2 2016 255
Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc, H2 2016 256
Non-Hodgkin Lymphoma - Pipeline by Moleculin Biotech Inc, H2 2016 257
Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd, H2 2016 258
Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H2 2016 259
Non-Hodgkin Lymphoma - Pipeline by Mundipharma International Ltd, H2 2016 260
Non-Hodgkin Lymphoma - Pipeline by NantKwest Inc, H2 2016 261
Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc, H2 2016 262
Non-Hodgkin Lymphoma - Pipeline by Nimbus Therapeutics LLC, H2 2016 263
Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016 264
Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt Ltd, H2 2016 265
Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2016 266
Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H2 2016 267
Non-Hodgkin Lymphoma - Pipeline by Oncobiologics Inc, H2 2016 268
Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics Inc, H2 2016 269
Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Inc, H2 2016 270
Non-Hodgkin Lymphoma - Pipeline by Oncternal Therapeutics Inc, H2 2016 271
Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 272
Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H2 2016 273
Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H2 2016 274
Non-Hodgkin Lymphoma - Pipeline by OXIS International, Inc., H2 2016 275
Non-Hodgkin Lymphoma - Pipeline by Panacea Biotec Ltd, H2 2016 276
Non-Hodgkin Lymphoma - Pipeline by Patrys Ltd, H2 2016 277
Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc, H2 2016 278
Non-Hodgkin Lymphoma - Pipeline by Pharma Mar SA, H2 2016 279
Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics Inc, H2 2016 280
Non-Hodgkin Lymphoma - Pipeline by Philogen SpA, H2 2016 281
Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals Inc, H2 2016 282
Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals Inc, H2 2016 283
Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd, H2 2016 284
Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 285
Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H2 2016 286
Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H2 2016 287
Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt, H2 2016 288
Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H2 2016 289
Non-Hodgkin Lymphoma - Pipeline by Sanofi, H2 2016 290
Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H2 2016 291
Non-Hodgkin Lymphoma - Pipeline by SciTech Development LLC, H2 2016 292
Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics Inc, H2 2016 293
Non-Hodgkin Lymphoma - Pipeline by Selvita SA, H2 2016 295
Non-Hodgkin Lymphoma - Pipeline by Senhwa Biosciences Inc, H2 2016 296
Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2016 297
Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2016 298
Non-Hodgkin Lymphoma - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016 299
Non-Hodgkin Lymphoma - Pipeline by SialoTec GmbH, H2 2016 300
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau SpA, H2 2016 301
Non-Hodgkin Lymphoma - Pipeline by Simcere Pharmaceutical Group, H2 2016 302
Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma KK, H2 2016 303
Non-Hodgkin Lymphoma - Pipeline by Soligenix Inc, H2 2016 304
Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics Inc, H2 2016 305
Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 306
Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics Inc, H2 2016 307
Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc, H2 2016 308
Non-Hodgkin Lymphoma - Pipeline by Sutro Biopharma Inc, H2 2016 309
Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 310
Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company Ltd, H2 2016 311
Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc, H2 2016 312
Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 313
Non-Hodgkin Lymphoma - Pipeline by Targazyme Inc, H2 2016 314
Non-Hodgkin Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H2 2016 315
Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 316
Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics Inc, H2 2016 317
Non-Hodgkin Lymphoma - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 318
Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H2 2016 319
Non-Hodgkin Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 320
Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Ltd, H2 2016 321
Non-Hodgkin Lymphoma - Pipeline by Transgene SA, H2 2016 322
Non-Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc, H2 2016 323
Non-Hodgkin Lymphoma - Pipeline by United BioPharma Inc, H2 2016 324
Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics Inc, H2 2016 325
Non-Hodgkin Lymphoma - Pipeline by Verastem Inc, H2 2016 326
Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H2 2016 327
Non-Hodgkin Lymphoma - Pipeline by Xencor Inc, H2 2016 328
Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences (UK) Ltd, H2 2016 329
Non-Hodgkin Lymphoma - Pipeline by ZIOPHARM Oncology Inc, H2 2016 330
Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc, H2 2016 331
Assessment by Monotherapy Products, H2 2016 332
Assessment by Combination Products, H2 2016 333
Number of Products by Stage and Target, H2 2016 335
Number of Products by Stage and Mechanism of Action, H2 2016 366
Number of Products by Stage and Route of Administration, H2 2016 396
Number of Products by Stage and Molecule Type, H2 2016 398
Non-Hodgkin Lymphoma - Dormant Projects, H2 2016 1573
Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H2 2016 1574
Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H2 2016 1575
Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H2 2016 1576
Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H2 2016 1577
Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H2 2016 1578
Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H2 2016 1579
Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H2 2016 1580
Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H2 2016 1581
Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H2 2016 1582
Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H2 2016 1583
Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H2 2016 1584
Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H2 2016 1585
Non-Hodgkin Lymphoma - Dormant Projects (Contd..13), H2 2016 1586
Non-Hodgkin Lymphoma - Dormant Projects (Contd..14), H2 2016 1587
Non-Hodgkin Lymphoma - Dormant Projects (Contd..15), H2 2016 1588
Non-Hodgkin Lymphoma - Dormant Projects (Contd..16), H2 2016 1589
Non-Hodgkin Lymphoma - Dormant Projects (Contd..17), H2 2016 1590
Non-Hodgkin Lymphoma - Dormant Projects (Contd..18), H2 2016 1591
Non-Hodgkin Lymphoma - Dormant Projects (Contd..19), H2 2016 1592
Non-Hodgkin Lymphoma - Dormant Projects (Contd..20), H2 2016 1593
Non-Hodgkin Lymphoma - Dormant Projects (Contd..21), H2 2016 1594
Non-Hodgkin Lymphoma - Dormant Projects (Contd..22), H2 2016 1595
Non-Hodgkin Lymphoma - Dormant Projects (Contd..23), H2 2016 1596
Non-Hodgkin Lymphoma - Dormant Projects (Contd..24), H2 2016 1597
Non-Hodgkin Lymphoma - Dormant Projects (Contd..25), H2 2016 1598
Non-Hodgkin Lymphoma - Dormant Projects (Contd..26), H2 2016 1599
Non-Hodgkin Lymphoma - Dormant Projects (Contd..27), H2 2016 1600
Non-Hodgkin Lymphoma - Dormant Projects (Contd..28), H2 2016 1601
Non-Hodgkin Lymphoma - Dormant Projects (Contd..29), H2 2016 1602
Non-Hodgkin Lymphoma - Dormant Projects (Contd..30), H2 2016 1603
Non-Hodgkin Lymphoma - Dormant Projects (Contd..31), H2 2016 1604
Non-Hodgkin Lymphoma - Dormant Projects (Contd..32), H2 2016 1605
Non-Hodgkin Lymphoma - Discontinued Products, H2 2016 1606
Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H2 2016 1607
Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H2 2016 1608
Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H2 2016 1609
Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H2 2016 1610
Non-Hodgkin Lymphoma - Discontinued Products (Contd..5), H2 2016 1611
Non-Hodgkin Lymphoma - Discontinued Products (Contd..6), H2 2016 1612
Non-Hodgkin Lymphoma - Discontinued Products (Contd..7), H2 2016 1613
Non-Hodgkin Lymphoma - Discontinued Products (Contd..8), H2 2016 1614
Non-Hodgkin Lymphoma - Discontinued Products (Contd..9), H2 2016 1615
Non-Hodgkin Lymphoma - Discontinued Products (Contd..10), H2 2016 1616
Non-Hodgkin Lymphoma - Discontinued Products (Contd..11), H2 2016 1617
Non-Hodgkin Lymphoma - Discontinued Products (Contd..12), H2 2016 161
List of Figures
Number of Products under Development for Non-Hodgkin Lymphoma, H2 2016 58
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2016 59
Number of Products under Development by Companies, H2 2016 60
Number of Products under Investigation by Universities/Institutes, H2 2016 77
Comparative Analysis by Late Stage Development, H2 2016 79
Comparative Analysis by Clinical Stage Development, H2 2016 80
Comparative Analysis by Early Stage Products, H2 2016 81
Assessment by Monotherapy Products, H2 2016 332
Assessment by Combination Products, H2 2016 333
Number of Products by Top 10 Targets, H2 2016 334
Number of Products by Stage and Top 10 Targets, H2 2016 334
Number of Products by Top 10 Mechanism of Actions, H2 2016 365
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 365
Number of Products by Top 10 Routes of Administration, H2 2016 395
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 395
Number of Products by Top 10 Molecule Types, H2 2016 397
Number of Products by Stage and Top 10 Molecule Types, H2 2016 397
